Cinacalcet
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | DRUG-CINACALCET |
|---|---|
| Art | Arzneimittel |
| Aliase | MimparaSensiparЦинакалцет |
| Status | reviewed 2026-07-11 | pending_clinical_signoff |
| Erkrankungen | DIS-PARATHYROID-CARCINOMA |
| Quellen | SRC-NCCN-THYROID-2025 |
Drug Facts
| Klasse | Calcimimetic (Calcium-sensing Rezeptor allosterischer Agonist) |
|---|---|
| Verfahren | Allosterisch erhöht sich die Empfindlichkeit des parathyroiden Calcium-Sensing-Rezeptors (CaSR) gegenüber extrazellulärem Kalzium, unterdrückt die PTH-Sekretion und senkt das Serumkalzium. Er wirkt auf die biochemische Folge der Erkrankung (PTH-getriebene Hyperkalzämie) anstatt auf den Tumor selbst – keine direkte antitumor / zytotoxische Wirkung. |
| Typische Dosierung | Initiate 30 mg PO BID. Titrate no more frequently than every 2-4 weeks through sequential doses of 30 mg BID → 60 mg BID → 90 mg BID → 90 mg TID → 90 mg QID (maximum labeled dose) to normalize serum calcium. Take with food (improves bioavailability). Check serum calcium within 1 week of initiation or any dose change. FDA-approved specifically for hypercalcemia of parathyroid carcinoma (also approved for secondary hyperparathyroidism in dialysis-dependent CKD and severe hypercalcemia in primary hyperparathyroidism when parathyroidectomy is not appropriate). |
| Ukraine registriert | Falsch |
| NSZU erstattet | Falsch |
| Ukraine zuletzt überprüft | 2026-07-11 |
Anmerkungen
STUB pending clinical co-lead signoff (CHARTER §6.1 — dev-mode- exempted draft content, not published/verified clinical advice). Cinacalcet is the only FDA-approved medical therapy specifically labeled for hypercalcemia of parathyroid carcinoma. It has no cytostatic/cytotoxic effect on the tumor — it controls the biochemical consequence (PTH-driven hypercalcemia) in unresectable, recurrent, or metastatic disease. Distinct from bisphosphonates (DRUG-ZOLEDRONATE) / denosumab (DRUG-DENOSUMAB) — already in the KB — which act on osteoclast-mediated bone turnover to prevent skeletal-related events from bone metastases rather than suppressing PTH secretion; the two mechanisms are complementary and may be used concurrently in refractory hypercalcemia, per the parent Disease entity's narrative (DIS-PARATHYROID-CARCINOMA).
Verwendet von
Erkrankung
DIS-PARATHYROID-CARCINOMA- Nebenschilddrüsenkarzinom
Therapieschema
REG-CINACALCET-HYPERCALCEMIA- Cinacalcet zur Hyperkalzämie des Nebenschilddrüsenkarzinoms